TOMEGLOVIR

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H27N3O4S
Molecular Weight	441.543
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C1=CC=CC2=C(C=CC=C12)S(=O)(=O)NC3=CC=C(NC(=O)C(C)(C)CO)C=C3

InChI

InChIKey=OSQAKHSYTKBSPB-UHFFFAOYSA-N

InChI=1S/C23H27N3O4S/c1-23(2,15-27)22(28)24-16-11-13-17(14-12-16)25-31(29,30)21-10-6-7-18-19(21)8-5-9-20(18)26(3)4/h5-14,25,27H,15H2,1-4H3,(H,24,28)

HIDE SMILES / InChI

Molecular Formula	C23H27N3O4S
Molecular Weight	441.543
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15652969 | https://www.ncbi.nlm.nih.gov/pubmed/12323400 | https://adisinsight.springer.com/drugs/800012718

Tomeglovir (BAY 38-4766) is a human cytomegalovirus (CMV) terminase complex inhibitor. Treatment with BAY 38-4766 reduced both viremia and DNAemia, as determined by a real-time PCR assay, following guinea pig cytomegalovirus (GPCMV) infection of cyclophosphamide-immunosuppressed strain 2 guinea pigs. BAY 38-4766 also reduced mortality following lethal GPCMV challenge in immunosuppressed Hartley guinea pigs. a combination of BAY 38-4766 with anti-cytomegalovirus drug ganciclovir showed antagonism. Interaction of viral DNA processing inhibitor 2-bromo-5,6-dichloro-1beta-D-ribofuranosyl benzimidazole (BDCRB) with BAY 38-4766 showed a mixed pattern of synergy and antagonism. Tomeglovir had been in phase II clinical trials by Bayer for the treatment of CMV infection. However, this development was discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
CHEMBL3991482: DNA terminase, Human cytomegalovirus 1 Target ID: CHEMBL3991482: DNA terminase, Human cytomegalovirus Sources: https://adisinsight.springer.com/drugs/800012718\|https://www.ncbi.nlm.nih.gov/pubmed/11428244\|https://www.ncbi.nlm.nih.gov/pubmed/28827420	Inhibitor 8504		0.34 µM [IC50]

PubMed

Title	Date	PubMed
The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs.	2005-01	15652969
Antiviral therapies.	2004-04	15062765
Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus.	2002-10	12323400
[Drugs against human cytomegalovirus].	2002-09	12474580
Focus on new drugs in development against human cytomegalovirus.	2002	12215056
Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action.	2001-12	11733458
Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir.	2001-10	11557492
A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.	2001-10	11533171
Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo.	2001-03	11428244

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:17:52 GMT 2025` Edited by `admin` on `Mon Mar 31 19:17:52 GMT 2025`
Record UNII	0YPQ44B589
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TOMEGLOVIR

Official Name

English

BAY-384766

Preferred Name

English

tomeglovir [INN]

Common Name

English

BAY-38-4766

Code

English

Tomeglovir [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C281